Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Avadel Pharmaceuticals Plc (AVDL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 92,160
  • Shares Outstanding, K 37,012
  • Annual Sales, $ 173,250 K
  • Annual Income, $ 68,270 K
  • 36-Month Beta 1.59
  • Price/Sales 0.81
  • Price/Cash Flow 5.92
  • Price/Book 1.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +356,885.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.69 +47.34%
on 12/26/18
3.17 -21.45%
on 01/08/19
+0.48 (+23.88%)
since 12/21/18
3-Month
1.69 +47.34%
on 12/26/18
4.54 -45.15%
on 10/30/18
-1.56 (-38.52%)
since 10/22/18
52-Week
1.69 +47.34%
on 12/26/18
11.93 -79.13%
on 01/25/18
-8.73 (-77.81%)
since 01/22/18

Most Recent Stories

More News
Do Options Traders Know Something About Avadel Pharmaceuticals (AVDL) Stock We Don't?

Investors need to pay close attention to Avadel Pharmaceuticals (AVDL) stock based on the movements in the options market lately.

AVDL : 2.49 (-2.35%)
Avadel Pharmaceuticals Announces Changes to Management Team and Board of Directors

- Michael S. Anderson resigns as Chief Executive Officer and member of Avadel's Board of Directors -

AVDL : 2.49 (-2.35%)
Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA

Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.

AVDL : 2.49 (-2.35%)
JAZZ : 128.66 (-0.32%)
NVS : 88.54 (+0.25%)
BLCM : 3.23 (-4.44%)
Avadel Pharmaceuticals Appoints Kevin Kotler to the Company's Board of Directors

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that Kevin Kotler, the...

AVDL : 2.49 (-2.35%)
BDSI : 4.10 (-5.09%)
Report: Developing Opportunities within Eaton Vance, IDT, Hemispherx BioPharma, Edgewell Personal Care, Rockwell Medical, and Avadel Pharmaceuticals -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eaton Vance Corporation (NYSE:EV),...

EV : 39.25 (-1.13%)
AVDL : 2.49 (-2.35%)
HEB : 0.22 (unch)
RMTI : 3.13 (-9.80%)
IDT : 6.80 (-2.58%)
EPC : 38.75 (+0.96%)
As Waking Up Multiple Times a Night to Urinate Can Lead to Memory Deficits, Obesity, Lowered Sex Drive, Falls and Depression, a New Council Urges Awareness and Action

Nov. 25-30 acknowledges Nocturia Awareness Week, part of Bladder Health Month, which encourages people to take control of their urinary health. Nocturia, a treatable medical condition that forces you to...

AVDL : 2.49 (-2.35%)
ASL Strategic Value Fund Releases Letter to Avadel Pharmaceuticals Board of Directors

The following is a letter that ASL Strategic Value Fund sent to the Board of Directors of Avadel Pharmaceuticals (NASDAQ:AVDL):

AVDL : 2.49 (-2.35%)
Avadel: 3Q Earnings Snapshot

DUBLIN (AP) _ Avadel Pharmaceuticals PLC (AVDL) on Monday reported a third-quarter loss of $15.8 million, after reporting a profit in the same period a year earlier.

AVDL : 2.49 (-2.35%)
Avadel Presents Data on Quality of Life Improvement in Patients on NOCTIVA(TM) at American Urological Association Western Annual Meeting

Patients treated with NOCTIVA were three times more likely to report no difficulty getting enough sleep and five times more likely to report no bother due to nocturia

AVDL : 2.49 (-2.35%)
Avadel Pharmaceuticals to Report Third Quarter 2018 Financial Results

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced it will report its third...

AVDL : 2.49 (-2.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AVDL with:

Business Summary

Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates...

See More

Key Turning Points

2nd Resistance Point 2.59
1st Resistance Point 2.54
Last Price 2.49
1st Support Level 2.46
2nd Support Level 2.42

See More

52-Week High 11.93
Fibonacci 61.8% 8.02
Fibonacci 50% 6.81
Fibonacci 38.2% 5.60
Last Price 2.49
52-Week Low 1.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar